Updates

August 11, 2026 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Business Responsibility & Sustainability Report for FY 2025-26 Pursuant to Regulations 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Business Responsibility & Sustainability Report of the Company for FY 2025-26. Kindly take the above information on record. Thanking you Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri E(), Mumbai– 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com 99 | Integrated Annual Report 2025-2026 ANNEXURE VI Business Responsibility & Sustainability Report SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identity Number (CIN) of the Listed Entity - L74900PN2011PLC139963 2. Name of the Listed Entity – Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) 3. Year of incorporation – 23rd June, 2011 4. Registered office address – Plot No 170-172 Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur, MH 413213 5. Corporate address - Technopolis Knowledge Park, 4th Floor, A wing, Office No. 401 to 407, Mahakali Caves Road, Andheri East, Mumbai - 400093 6. E-mail – complianceofficer@alivus.com 7. Telephone - 022-6829-7979 8. Website - www.alivus.com 9. Financial year for which reporting is being done – 2025-26 10. Name of the Stock Exchange(s) where shares are listed : Name of the Exchange Stock Code BSE Ltd. 543322 National Stock Exchange of India Ltd. ALIVUS 11. Paid-up Capital – ` 245.47 Million 12. Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report – Name: Rudalf Corriea Tel No. 022-6829-7979 Email address: complianceofficer@alivus.com 13. Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together). – The disclosures under this report are made on Standalone basis. 14. Name of assessment and assurance provided – Not Applicable for the reporting period as per SEBI Circular No. SEBI/ HO/CFD/CFD-PoD-1/P/CIR/2025/42 dt. 28th March 2025, however, independent limited assurance from the British Standards Institution (BSI) for its BRSR Core KPIs for FY 2025-26 was conducted voluntarily. 15. Type of assessment and assurance obtained – Not Applicable for the reporting period as per SEBI Circular No. SEBI/ HO/CFD/CFD-PoD-1/P/CIR/2025/42 dt. 28th March 2025, however, independent limited assurance from the British Standards Institution (BSI) for its BRSR Core KPIs for FY 2025-26 was conducted voluntarily. Note: Please note that the numbers have been rationalized in this year’s report, wherever required. Alivus Life Sciences Limited | 100 II. Products/Services 16. Details of business activities (accounting for 90% of the entity’s Turnover): Description of Main Activity Description of Business Activity % of Turnover of the entity 1. Manufacturing Chemical and chemical products, pharmaceuticals, 100.00 medicinal, chemical and botanical products. 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): Product/ Service NIC Code % of Turnover contributed 1. API (Active Pharmaceutical Ingredients) 21002 100.00 III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National** 4* 2* 6 International Nil Nil Nil * Registered Office and one of the manufacturing units have the same address. ** One of our manufacturing site at Chincholi is under construction this year, which is not considered in the above details. 19. Markets served by the entity: a. Number of locations: Location Number National (No. of States & UTs) 18+ International (No. of Countries) 75+ b. What is the contribution of exports as a percentage of the total turnover of the entity? 54.4% c. A brief on types of customers: The Company’s primary customers comprise end formulators, mainly pharmaceutical manufacturers engaged in producing finished pharmaceutical products using the Active Pharmaceutical Ingredients (APIs) supplied by the Company. These formulations are subjected to stringent quality and regulatory checks prior to being commercialised and distributed in global markets. At present, the Company caters to a broad and diversified customer base of more than 700 clients and maintains business relationships with the top 20 generic pharmaceutical companies worldwide, reflecting its significant footprint in the pharmaceutical industry. IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled): Sr. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 2272 2104 92.61 168 7.39 2. Other than permanent (E) 12 7 58.33 5 41.67 3. Total employees (D + E) 2284 2111 92.43 173 7.57 WORKERS 4. Permanent (F) 0 0 0.00 0 0.00 5. Other than permanent (G) 1666 1640 98.44 26 1.56 6. Total workers (F + G) 1666 1640 98.44 26 1.56 Note: Other than permanent employees and other than permanent workers include the contractual employees and workers. 101 | Integrated Annual Report 2025-2026 b. Differently abled employees and workers: Sr. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 4 3 75.00 1 25.00 2. Other than permanent (E) 0 0 0.00 0 0.00 3. Total differently abled employees (D + E) 4 3 75.00 1 25.00 DIFFERENTLY ABLED WORKERS 4. Permanent (F) 0 0 0.00 0 0.00 5. Other than permanent (G) 5 4 80.00 1 20.00 6. Total differently abled workers (F + G) 5 4 80.00 1 20.00 21. Participation/Inclusion/Representation of women: No. and percentage of Females Total (A) No. (B) % (B / A) Board of Directors 7 1 14.29 Key Management Personnel 4 0 0.00 Note: KMPs include the Managing Director, Executive Director, Chief Financial Officer and Company Secretary of the Company. 22. Turnover rate for permanent employees and workers (in percent): FY 2025-26 FY 2024-25 FY 2023-24 Male Female Total Male Female Total Male Female Total Permanent Employees 22.10 15.71 21.63 20.77 20.85 20.77 26.14 16.85 25.48 Permanent Workers The Company does not have any permanent workers V. Holding, Subsidiary and Associate Companies (including Joint Ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ventures: Name of the holding/ subsidiary/ Indicate whether holding/ % of shares Does the entity indicated at column A, associate companies/ joint Subsidiary/ Associate/ held by listed participate in the Business Responsibility ventures (A) Joint Venture entity initiatives of the listed entity? (Yes/No) 1. Nirma Limited Holding NA No VI. CSR Details 24. (i) Whether CSR is applicable as per section 135 of the Companies Act, 2013: Yes (ii) Turnover (in `) – 25,518 Million (iii) Net worth (in `) – 33,321 Million Alivus Life Sciences Limited | 102 VII. Transparency and Disclosures Compliances 25. Complaints/Grievance on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: Grievance Redressal Mechanis [Showing first 8,000 characters — download PDF for full document]